Fig. 3

The effect of E6-siRNA and Oxaliplatin combination on the cell apoptosis. A. E6-siRNA transfection increases the sensitivity of CaSki cells to Oxaliplatin. B, C. BAX and BCL2 expression levels increase and decrease due to combination therapy compared to control group, respectively. D. The Casp-3 expression had remarkably increased following combination therapy compared to monotherapy with either Oxaliplatin or E6-siRNA. E, F. The Casp-8 and Casp-9 expression resulting from combination therapy did not change significantly compared to other groups. G. The expression level of the p53 gene as a result of combination therapy showed a dramatic change compared to other genes involved in apoptosis and other groups (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)